1-1-7, Uchisaiwaicho, Chiyoda-ku
4-1, Technopark, Sanda
6-7-6, Minatojimaminamimachi, Chuo-ku, Kobe,
SPL works on the manufacture of AMITIZA and RESCULA
SPL manages the alliances with partners who sell RESCULA in Japan and Taiwan
SPL facilitates certain CMC, Pre-clinical and clinical activities, including lifecycle management for AMITIZA and research agreements with Japanese research universities
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.